The Chronic Lymphocytic Leukemia Channel is supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), Johnson & Johnson (Gold), BeOne Medicines (Silver) and Lilly (Silver).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ESH CLL 2026 | MRD-guided ibrutinib-venetoclax in CLL: insights from the ERADIC study
Anne-Sophie Michallet, MD, PhD, Léon Bérard Center, Lyon, France, discusses findings from the ERADIC study evaluating a measurable residual disease (MRD)-guided regimen of ibrutinib plus venetoclax in patients with intermediate-risk chronic lymphocytic leukemia (CLL). Dr Michallet highlights how longer treatment exposure improved rates of undetectable MRD. This interview took place at the ESH CLL 2026 congress in Stockholm, Sweden.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
Yes, we have published recently the ERADIC study. The ERADIC study is a study only for intermediate risk group of CLL for unmuted IGHV patients without TP53 and without complex karyotype. And in this study, we randomize between I plus V, driven by minimal residual disease and FCR. For the guided treatment with MRD is only in clinical trial because it’s very difficult to make the MRD guided strategy in routine...
Yes, we have published recently the ERADIC study. The ERADIC study is a study only for intermediate risk group of CLL for unmuted IGHV patients without TP53 and without complex karyotype. And in this study, we randomize between I plus V, driven by minimal residual disease and FCR. For the guided treatment with MRD is only in clinical trial because it’s very difficult to make the MRD guided strategy in routine. So in France, we did not use MRD to have a strategy in the routine practice, just in clinical trials. When we use the result of the ERADIC study, the patients have a minimal residual disease evaluation at month 9, at month 15, and at month 27. What I can say is that at month 9, there are few patients with undetectable minimal residual disease, but when we use I plus V in a longer time, at month 21 and month 27, we have an increased result of the depth of the undetectable minimal residual disease. So I think the long time of exposition of I plus V increased the undetectable minerals, which is deep.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
